The antidepressant desipramine is an arrestin-biased ligand at the α 2A-adrenergic receptor driving receptor down-regulation in vitro and in vivo

Academic Article


  • The neurobiological mechanisms of action underlying antidepressant drugs remain poorly understood. Desipramine (DMI) is an antidepressant classically characterized as an inhibitor of norepinephrine reuptake. Available evidence, however, suggests a mechanism more complex than simple reuptake inhibition. In the present study, we have characterized the direct interaction between DMI and the α 2A-adrenergic receptor (α 2AAR), a key regulator of noradrenergic neurotransmission with altered expression and function in depression. DMI alone was found to be sufficient to drive receptor internalization acutely and a robust down-regulation of α 2AAR expression and signaling following prolonged stimulation in vitro. These effects are achieved through arrestin-biased regulation of the receptor, as DMI selectively induces recruitment of arrestin but not activation of heterotrimeric G proteins. Meanwhile, a physiologically relevant concentration of endogenous agonist (norepinephrine) was unable to sustain a down-regulation response. Prolonged in vivo administration of DMI resulted in significant down-regulation of synaptic α 2AAR expression, a response that was lost in arrestin3-null animals. We contend that direct DMI-driven arrestin-mediated α 2AAR down-regulation accounts for the therapeutically desirable but mechanistically unexplained adaptive alterations in receptor expression associated with this antidepressant. Our results provide novel insight into both the pharmacology of this antidepressant drug and the targeting of the α 2AAR in depression. © 2011 by The American Society for Biochemistry and Molecular Biology, Inc.
  • Authors

    Published In

    Digital Object Identifier (doi)

    Author List

  • Cottingham C; Chen Y; Jiao K; Wang Q
  • Start Page

  • 36063
  • End Page

  • 36075
  • Volume

  • 286
  • Issue

  • 41